Matthew Harkenrider is an Oncology physician affiliated with Loyola University Medical Center. OpenAlex indexes 230 publications with 4,090 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2160 S 1st Ave
Maguire Center, Room 2944
Maywood, IL 601533328
Telephone
708-216-2575Provider last certified this registry record 23 Apr 2021.
Clinical trials
- Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Sponsor: Loyola University
- Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer
Sponsor: Loyola University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20248 payments
- VIEWRAY TECHNOLOGIES INCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
55.6%alpha-Adrenergic Blocker55.6%Tamsulosin Hcl100%Part D≥28 patientsCancer & immunology
16.7%Gonadotropin Releasing Hormone Receptor Antagonist16.7%Orgovyx100%Part D<11 patientsSensory organs
14.8%Fluoroquinolone Antibacterial14.8%Ciprofloxacin Hcl100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline
Practical Radiation Oncology
2022 - GEC-ESTRO (ACROP)–ABS–CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina
International Journal of Radiation Oncology*Biology*Physics
2022 - Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis
Radiotherapy and Oncology
2021 - Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial
International Journal of Radiation Oncology*Biology*Physics
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Patrick Stiff, MD
Loyola University Medical Center
Olufemi Kassim, MD
Loyola University Medical Center
Jose Biller, MD
Loyola University Medical Center
Kathy Albain, MD
Loyola University Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”